Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huolingshengji Granules in ALS
NCT04950933Phase 3Unknown
- Sponsor
- Peking University Third Hospital
- Start
- Jun 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of Huoling Shengji Granules in amyotrophic lateral sclerosis (ALS), sponsored by Peking University Third Hospital. Status: unknown.
02
Drugs
Huoling Shengji Granules
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04950933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04950933.